What is HC Wainwright’s Estimate for MLTX FY2027 Earnings?

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($3.11) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share.

Other analysts have also recently issued research reports about the stock. Zacks Research raised shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Oppenheimer upped their target price on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a research note on Friday, January 9th. BTIG Research lifted their target price on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and boosted their price target for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $27.85.

MoonLake Immunotherapeutics Trading Down 0.7%

MLTX opened at $18.02 on Wednesday. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75. The company has a fifty day moving average of $15.97 and a 200-day moving average of $22.25. The stock has a market cap of $1.16 billion, a PE ratio of -5.12 and a beta of 1.20. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.92). During the same quarter last year, the company posted ($0.72) EPS.

Insider Buying and Selling

In other news, CEO Da Silva Jorge Santos sold 130,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer directly owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the sale, the insider directly owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. The trade was a 64.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 402,908 shares of company stock worth $5,987,162. 12.02% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. purchased a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $509,000. Decheng Capital LLC purchased a new position in MoonLake Immunotherapeutics during the second quarter worth about $8,572,000. Elevation Point Wealth Partners LLC bought a new stake in MoonLake Immunotherapeutics in the 2nd quarter worth about $74,000. Caitong International Asset Management Co. Ltd grew its position in MoonLake Immunotherapeutics by 22,387.5% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock worth $606,000 after purchasing an additional 84,177 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at about $1,792,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.